<PAGE>
- --------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
-------------------------
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
-------------------------
DATE OF REPORT: OCTOBER 15, 1998
(Date of earliest event reported)
PHOTOGEN TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
NEVADA 0-23553 36-4010347
(State or other jurisdiction (Commission File Number) (I.R.S. Employer
of incorporation or Identification No.)
organization)
7327 OAK RIDGE HIGHWAY, SUITE B
KNOXVILLE, TENNESSEE 37931
(Address of principal executive offices) (Zip Code)
(423) 769-4011
(Registrant's telephone number including area code)
- -------------------------------------------------------------------------------
- -------------------------------------------------------------------------------
<PAGE>
ITEM 5. OTHER EVENTS.
Photogen Technologies, Inc. announced the signing of two research
agreements with Harvard Medical School affiliates in a press release dated
October 15, 1998, filed as Exhibit 99 hereto.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) The following exhibit is filed with this report:
99 Press release of the Company, dated October 15, 1998, announcing
the signing of two research agreements with Harvard Medical School
affiliates.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Photogen Technologies, Inc.
By: /s/ John Smolik
-----------------------
John Smolik, President
Date: October 15, 1998
<PAGE>
EXHIBIT INDEX
<TABLE>
<CAPTION>
Exhibit
No. Description
- ---- -----------
<S> <C>
99 Press release of the Company, dated October 15, 1998, announcing
the signing of two research agreements with Harvard Medical School
affiliates.
</TABLE>
<PAGE>
EXHIBIT 99
Photogen Technologies, Inc.
7327 Oak Ridge Highway
Knoxville, TN 37931
Voice: 423-769-4012
Fax: 423-769-4013
Internet: www.photogen.com
PHOTOGEN SIGNS TWO RESEARCH AGREEMENTS WITH HARVARD
MEDICAL SCHOOL AFFILIATES
KNOXVILLE, Tenn.--Oct. 15, 1998--Photogen Technologies, Inc. (OTC: PHGN) has,
through its subsidiary Photogen, Inc., signed research agreements with two
teaching affiliates of Harvard Medical School. The agreements come on the heels
of a September announcement that the former Dean of the Harvard Medical School,
Dr. Daniel Tosteson, has joined the Company's Scientific Advisory Council.
One research agreement - with Massachusetts General Hospital for work to be
carried out at its Center for Imaging and Pharmaceutical Research (CIPR) - will
evaluate treatment of prostate and lung cancer using Photogen's simultaneous
two-photon excitation technology. The other agreement - with the Massachusetts
Eye and Ear Infirmary (MEEI) - will initially evaluate the technology for
treatments of age-related macular degeneration (AMD) of the eye. Both
agreements provide that additional research projects may be undertaken with
Photogen.
"Teaming with prestigious leaders in cancer research and AMD like Harvard
Medical School, Mass General and The Massachusetts Eye and Ear Infirmary
gives us a wonderful opportunity to test our technology in a highly visible
setting," said John Smolik, president and CEO of Photogen. "These agreements
are an important step in our strategy of tapping the best minds and
facilities in academia and industry to examine our technologies in practical
applications. This is the first real test of our technology's ability to
offer the hope of treating specific diseases and conditions."
Dr. Gerald L. Wolf will be the Principal Investigator for the CIPR. He holds an
M.D. degree from Harvard Medical School, earned in 1968 and a Ph.D. in
Pharmacology and Physiology from Nebraska in 1965. Dr. Wolf has published more
that 150 scholarly papers, four books and numerous position papers in the fields
of contrast media, drug development and functional imaging. Dr. Wolf is widely
known for his work in the areas of cancer detection and treatment.
MEEI's Principal Investigator will be Dr. Joan W. Miller, a renown researcher in
the field of macular degenerative disease. She earned her M.D. from Harvard
Medical School in 1985 and has more than 50 scientific and scholarly
publications to her credit. Clinical interests include diseases and surgery of
the retina and vitreous, macular degeneration and diabetic retinopathy.
<PAGE>
Photogen intends ultimately to use the data gained through these animal studies
and future clinical trials to speed submissions for regulatory approvals,
although this is dependent largely upon the Company's ability to secure
favorable industry collaborative agreements for manufacturing and distribution.
Both agreements enable Photogen to combine its technology with the scientific
expertise, laboratory facilities and personnel provided by MEEI and CIPR. MEEI
and Mass General each has the right to patent any new inventions arising out of
the research pursuant to their respective projects, and Photogen has the right
to obtain an exclusive license concerning the invention on terms to be
negotiated after development of the invention.
About Lung Cancer
Most types of lung cancer can be categorized into small cell and nonsmall cell.
In general, the small cell type has usually spread by the time of diagnosis and
is treated by chemotherapy and/or radiation therapy. The nonsmall type may not
have spread at the time of diagnosis, and surgical resection of this type may be
possible. Metastatic lung cancer (the spread of cancer) can occur to almost any
area of the body with common sites being the brain, bone, bone marrow and liver.
The peak incidence occurs between 55 and 65 years old. The incidence is 1 out of
1,000 people. Photogen's agreement with CIPR will look at possible treatments
for lung cancer using two-photon excitation technology. (More info on lung
cancer at www.drkoop.com/resource/cancer.)
About Prostate Cancer
Prostate cancer is a malignancy that develops in the prostate gland, a gland
that is important for the proper function of the male reproductive tract. Cancer
of the prostate is the most common cancer among American men affecting about one
in five men during the course of a lifetime. Although incidence increases with
age, this cancer can occur in younger men as well. This form of cancer very
often occurs even without symptoms. Photogen's agreement with CIPR also will
look at treatments for prostate cancer using two-photon excitation technology.
(More info on prostate cancer at www.drkoop.com/resource/cancer.)
About Age-Related Macular Degeneration (AMD)
According to the American Academy of Ophthalmology (www.eyenet.org) and the
International Association of Online Ophthalmologists, (www.isoo.org), AMD
affects up to 13 million Americans by progressively damaging the center
portion of the retina. AMD is a leading cause of reduced eyesight in the
senior population, rarely seen before age sixty. Patients lose the ability to
look straight ahead and distinguish fine detail or read small print, and must
eventually rely on peripheral vision. Eighty percent of AMD cases are the
"dry" form, which cannot be treated and causes gradual vision loss. The
remaining cases are the more severe "wet" form, in which abnormal blood
vessels grow under the retina. It is the "wet" form that the research between
Photogen and MEEI aims to address.
<PAGE>
About Photogen
Photogen's scientists are working toward the development of its proprietary
multi-photon excitation technology to enhance the safety and efficacy of
photodynamic therapy for the diagnosis and treatment of cancer, infectious
diseases and other medical conditions.
Photogen Technologies, Inc., through its wholly owned subsidiary -- Photogen,
Inc. -- is a development-stage company focused on creating photodynamic-related
health care products based on its proprietary multi-photon excitation and
related technology. The Company has discovered new methods for using
laser-generated light to activate photoactive agents within deep tissue
sufficient to produce a range of beneficial therapeutic and diagnostic outcomes.
These technologies involve methods, materials and devices that may be used to
produce light and photoactive agents that will destroy diseased cells, remove
tissue or identify and diagnose disease.
This news release may contain forward-looking statements that involve risks and
uncertainties. The Company has no products or operating revenues at this time. A
full discussion of the Company's operations and financial condition, including
risk factors that may affect the Company's business and future prospects, is
contained in documents the company files with the Securities and Exchange
Commission, such as the Company's reports on Form 10-QSB, Form 10-KSB and Form
8-K. These documents identify important factors that could cause the Company's
actual performance to differ from current expectations. The common stock of
Photogen Technologies, Inc. is traded on the over-the-counter bulletin board
market under the symbol PHGN.
For information, contact Robert Cathey at Ackermann Public Relations &
Marketing, 423/584-0550, e-mail: [email protected]. Or, visit our World
Wide Web site, at www.photogen.com.
